圣诺生物：公司产品拟中选国家组织集采药品接续采购

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is participating in the national centralized procurement of medicines, which includes multiple products selected in recent rounds of procurement [1] Group 1: Procurement Participation - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection, and Somatostatin Injection (both selected in the eighth batch), are part of the national procurement initiative [1] - The company is also proposing new products for selection in the upcoming procurement round, including Thymosin Alpha 1 Injection and Exenatide Injection [1]